Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C De Lorenzo
Two Novel Human Anti-ErbB2 Immunoagents Are Active on Trastuzumab-Resistant Tumours
British Journal of Cancer
Cancer Research
Oncology
Related publications
Effects of a Second-Generation Human Anti-ErbB2 ImmunoRNase on Trastuzumab-Resistant Tumors and Cardiac Cells
Protein Engineering, Design and Selection
Biochemistry
Bioengineering
Molecular Biology
Biotechnology
Enzastaurin Inhibits Tumours Sensitive and Resistant to Anti-Egfr Drugs
British Journal of Cancer
Cancer Research
Oncology
Nectin-4 Cis-Interacts With ErbB2 and Its Trastuzumab-Resistant Splice Variants, Enhancing Their Activation and DNA Synthesis
Scientific Reports
Multidisciplinary
Preexisting Oncogenic Events Impact Trastuzumab Sensitivity in ERBB2-amplified Gastroesophageal Adenocarcinoma
Journal of Clinical Investigation
Medicine
Anti-Igf-1r Monoclonal Antibody Inhibits the Carcinogenicity Activity of Acquired Trastuzumab-Resistant SKOV3
Journal of Ovarian Research
Gynecology
Oncology
Obstetrics
Structure Determination of Active Full Length Human Taspase1: Towards Novel Anti-Cancer Therapeutics
Biophysical Journal
Biophysics
Indoleamides Are Active Against Drug-Resistant Mycobacterium Tuberculosis
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
The Anti-erbB3 Antibody MM-121/SAR256212 in Combination With Trastuzumab Exerts Potent Antitumor Activity Against Trastuzumab-Resistant Breast Cancer Cells
Molecular Cancer
Cancer Research
Oncology
Molecular Medicine
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
